Form 4: Akero Therapeutics CFO Acquires Shares and Stock Options

Akero Therapeutics' Chief Financial Officer, William Richard White, acquired 24,300 restricted stock units and 73,700 stock options on December 16, 2024.

Summary

• William Richard White, the Chief Financial Officer of Akero Therapeutics, acquired 24,300 restricted stock units (RSUs) and 73,700 stock options on December 16, 2024.
• The RSUs vest in eight equal semi-annual installments starting December 16, 2024, contingent on continuous service.
• The stock options vest in 48 equal monthly installments starting December 16, 2024, also contingent on continuous service.
• The stock options have an exercise price of $29.23 and expire on December 15, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant to a key executive, which is generally a positive sign of alignment and commitment. There are no negative implications.

Positives

• The acquisition of shares and options by the CFO indicates confidence in the company's future performance.
• The vesting schedules for both RSUs and options incentivize long-term commitment from the CFO.

Risks

• The vesting of the RSUs and options is contingent on the CFO's continuous service, which could be a risk if the CFO leaves the company before full vesting.

Future Outlook

The vesting of the RSUs and stock options is tied to the CFO's continued service with the company, suggesting a focus on long-term stability and performance.

Industry Context

This type of equity compensation is common in the biotech industry to align management's interests with those of shareholders and to incentivize long-term growth.

Comparison to Industry Standards

• Equity grants to executives are a standard practice in the biotech industry, often including a mix of stock options and restricted stock units.
• Vesting schedules are typically structured to encourage long-term commitment, with monthly or semi-annual vesting periods being common.
• The specific terms of the grants, such as the exercise price and vesting schedule, are often tailored to the individual executive and the company's specific circumstances.

Stakeholder Impact

• The equity grants align the CFO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.
• The vesting schedule incentivizes the CFO to remain with the company, which can provide stability and continuity.

Key Dates

Keywords

Akero Therapeutics, AKRO, CFO, William Richard White, stock options, restricted stock units, RSUs, insider trading, equity compensation, vesting